Invasive aspergillosis: Is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? | Zendy

Jorge Garbino | Zendy; Gabriel Schnetzler | Zendy; Craig S. Roberts | Zendy

Open Access

Invasive aspergillosis: Is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?

Author(s) -

Jorge Garbino,

Gabriel Schnetzler,

Craig S. Roberts

Publication year - 2006

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2006.11259

Subject(s) - voriconazole , medicine , amphotericin b , aspergillosis , tolerability , regimen , cost effectiveness , surgery , intensive care medicine , adverse effect , antifungal , immunology , risk analysis (engineering) , dermatology

Voriconazole for the treatment of invasive aspergillosis (IA) shows superior clinical outcome and tolerability compared to conventional amphotericin B. However, the latter is often used as initial treatment due to lower drug acquisition costs. Therefore we performed a cost-effectiveness analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research